Literature DB >> 31960544

Fatty acid amide hydrolase is lower in young cannabis users.

Maya R Jacobson1,2,3, Jeremy J Watts1,2,3, Tania Da Silva1,3, Rachel F Tyndale2,4,3, Pablo M Rusjan1,4,3, Sylvain Houle1,4,3, Alan A Wilson1,4, Ruth A Ross2, Isabelle Boileau1,4,3, Romina Mizrahi1,2,4,3.   

Abstract

We have recently shown that levels of fatty acid amide hydrolase (FAAH), the enzyme that metabolizes the endocannabinoid anandamide, are lower in the brains of adult cannabis users (CUs) (34 ± 11 years of age), tested during early abstinence. Here, we examine replication of the lower FAAH levels in a separate, younger cohort (23 ± 5 years of age). Eighteen healthy volunteers (HVs) and fourteen CUs underwent a positron emission tomography scan using the FAAH radioligand [11 C]CURB. Regional [11 C]CURB binding was calculated using an irreversible two-tissue compartment model with a metabolite-corrected arterial plasma input function. The FAAH C385A genetic polymorphism (rs324420) was included as a covariate. All CUs underwent a urine screen to confirm recent cannabis use and had serum cannabinoids measured. One CU screened negative for cannabinoids via serum and was removed from analysis. All HVs reported less than five lifetime cannabis exposures more than a month prior to study initiation. There was a significant effect of group (F1,26 = 4.31; P = .048) when two A/A (rs324420) HVs were removed from analysis to match the genotype of the CU group (n = 16 HVs, n = 13 CUs). Overall, [11 C]CURB λk3 was 12% lower in CU compared with HV. Exploratory correlations showed that lower brain [11 C]CURB binding was related to greater use of cannabis throughout the past year. We confirmed our previous report and extended these findings by detecting lower [11 C]CURB binding in a younger cohort with less cumulative cannabis exposure.
© 2020 Society for the Study of Addiction.

Entities:  

Keywords:  [11C]CURB; addiction; anandamide; cannabis; fatty acid amide hydrolase; positron emission tomography

Mesh:

Substances:

Year:  2020        PMID: 31960544      PMCID: PMC7944390          DOI: 10.1111/adb.12872

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  43 in total

1.  Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain.

Authors:  J Villares
Journal:  Neuroscience       Date:  2007-01-10       Impact factor: 3.590

2.  The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.

Authors:  Isabelle Boileau; Rachel F Tyndale; Belinda Williams; Esmaeil Mansouri; Duncan J Westwood; Bernard Le Foll; Pablo M Rusjan; Romina Mizrahi; Vincenzo De Luca; Qian Zhou; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-03       Impact factor: 6.200

3.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  The drug abuse screening test.

Authors:  H A Skinner
Journal:  Addict Behav       Date:  1982       Impact factor: 3.913

5.  Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.

Authors:  Deepak Cyril D'Souza; Jose A Cortes-Briones; Mohini Ranganathan; Halle Thurnauer; Gina Creatura; Toral Surti; Beata Planeta; Alexander Neumeister; Brian Pittman; Marc Normandin; Michael Kapinos; Jim Ropchan; Yiyun Huang; Richard E Carson; Patrick D Skosnik
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-01-01

6.  Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.

Authors:  Isabelle Boileau; Pablo M Rusjan; Belinda Williams; Esmaeil Mansouri; Romina Mizrahi; Vincenzo De Luca; Douglas S Johnson; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-17       Impact factor: 6.200

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

8.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

Review 9.  Microglia activation states and cannabinoid system: Therapeutic implications.

Authors:  M Mecha; F J Carrillo-Salinas; A Feliú; L Mestre; C Guaza
Journal:  Pharmacol Ther       Date:  2016-06-29       Impact factor: 12.310

10.  Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions.

Authors:  S Zhuang; J Kittler; E V Grigorenko; M T Kirby; L J Sim; R E Hampson; S R Childers; S A Deadwyler
Journal:  Brain Res Mol Brain Res       Date:  1998-11-20
View more
  5 in total

1.  Serum lipid analysis and isotopic enrichment is suggestive of greater lipogenesis in young long-term cannabis users: A secondary analysis of a case-control study.

Authors:  Giulia Cisbani; Alex Koppel; Adam H Metherel; Mackenzie E Smith; Kankana N Aji; Ana C Andreazza; Romina Mizrahi; Richard P Bazinet
Journal:  Lipids       Date:  2022-01-24       Impact factor: 1.880

2.  Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.

Authors:  Jeremy J Watts; Maya R Jacobson; Nittha Lalang; Isabelle Boileau; Rachel F Tyndale; Michael Kiang; Ruth A Ross; Sylvain Houle; Alan A Wilson; Pablo Rusjan; Romina Mizrahi
Journal:  Biol Psychiatry       Date:  2020-03-12       Impact factor: 13.382

3.  Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder.

Authors:  Erin L Martin; Aimee L McRae-Clark
Journal:  Curr Addict Rep       Date:  2020-11-09

Review 4.  Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.

Authors:  Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang
Journal:  J Med Chem       Date:  2020-12-30       Impact factor: 7.446

Review 5.  Biomarkers of the Endocannabinoid System in Substance Use Disorders.

Authors:  Francisco Navarrete; María S García-Gutiérrez; Ani Gasparyan; Daniela Navarro; Francisco López-Picón; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Biomolecules       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.